FDA Hit With Slew Of Suits As Firms Fight For Market Advantage
Executive Summary
At least nine complaints have been filed against the agency since March, most involving market exclusivity claims; lawyers expect innovators will be pursuing more cases as patents expire and biosimilars emerge.